Hikma Outlines Injectables Growth Amid Slow Start For Generics
Generics Revenues Expected To Be Weighted Towards Second Half Of 2022
• By David Wallace
Hikma has set out its injectables growth expectations after acquiring Custopharm • Source: Christian Horz / Alamy Stock Photo 
